{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:35:56Z","timestamp":1761856556612,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.esmoop.2023.102196","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T18:45:23Z","timestamp":1703011523000},"page":"102196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD)"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-7286","authenticated-orcid":false,"given":"L.","family":"Incorvaia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Novo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Brando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.R.","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Toss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-4397","authenticated-orcid":false,"given":"Z.","family":"Ballatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7169-3463","authenticated-orcid":false,"given":"M.","family":"Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.D.","family":"Bazan Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gristina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Galvano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Damerino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Bazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2023.102196_bib1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2023.102196_bib2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc.2016.72","article-title":"Hereditary breast and ovarian cancer: new genes in confined pathways","volume":"16","author":"Nielsen","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"10.1016\/j.esmoop.2023.102196_bib3","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.esmoop.2023.102196_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2020.12.023","article-title":"Clinical practice guidelines for BRCA1 and BRCA2 genetic testing","volume":"146","author":"Pujol","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102196_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100459","article-title":"Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies","volume":"7","author":"Russo","year":"2022","journal-title":"ESMO Open"},{"issue":"26","key":"10.1016\/j.esmoop.2023.102196_bib6","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.21.01532","article-title":"Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline","volume":"39","author":"Tung","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102196_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100235","article-title":"Impact of deleterious variants in other genes beyond BRCA1\/2 detected in breast\/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge","volume":"6","author":"Bono","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2023.102196_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.682445","article-title":"Prevalence and spectrum of germline BRCA1 and BRCA2 variants of uncertain significance in breast\/ovarian cancer: mysterious signals from the genome","volume":"11","author":"Fanale","year":"2021","journal-title":"Front Oncol"},{"issue":"1-2","key":"10.1016\/j.esmoop.2023.102196_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1383-5718(01)00162-0","article-title":"Evidence for DNA damage in patients with coronary artery disease","volume":"493","author":"Botto","year":"2001","journal-title":"Mutat Res"},{"key":"10.1016\/j.esmoop.2023.102196_bib10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncomms1601","article-title":"BRCA1 is an essential regulator of heart function and survival following myocardial infarction","volume":"2","author":"Shukla","year":"2011","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.esmoop.2023.102196_bib11","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1074\/jbc.M111.292664","article-title":"BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure","volume":"287","author":"Singh","year":"2012","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102196_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10549-016-3678-2","article-title":"Cardiac function in BRCA1\/2 mutation carriers with history of breast cancer treated with anthracyclines","volume":"155","author":"Barac","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102196_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10549-016-4101-8","article-title":"The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy","volume":"162","author":"Pearson","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102196_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/genes8020059","article-title":"An exploratory study to determine whether BRCA1 and BRCA2 mutation carriers have higher risk of cardiac toxicity","volume":"8","author":"Sajjad","year":"2017","journal-title":"Genes (Basel)"},{"issue":"11","key":"10.1016\/j.esmoop.2023.102196_bib15","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum Mutat"},{"issue":"Database issue","key":"10.1016\/j.esmoop.2023.102196_bib16","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102196_bib17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102196_bib18","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3390\/cancers12051158","article-title":"Hereditary breast and ovarian cancer in families from Southern Italy (Sicily)-prevalence and geographic distribution of pathogenic variants in BRCA1\/2 genes","volume":"12","author":"Incorvaia","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.esmoop.2023.102196_bib19","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102196_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103436","article-title":"The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC\/IAP-SIBioC-SIF Italian Scientific Societies","volume":"165","author":"Russo","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5645","key":"10.1016\/j.esmoop.2023.102196_bib21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2023.102196_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975326","article-title":"BRCA1\/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients","volume":"12","author":"Incorvaia","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.102196_bib23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/gim.2014.40","article-title":"Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients","volume":"16","author":"LaDuca","year":"2014","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.esmoop.2023.102196_bib24","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.3390\/cancers12092415","article-title":"Detection of germline mutations in a cohort of 139 patients with bilateral breast cancer by multi-gene panel testing: impact of pathogenic variants in other genes beyond BRCA1\/2","volume":"12","author":"Fanale","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102196_bib25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/jnci\/djaa023","article-title":"The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort","volume":"112","author":"Hu","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.esmoop.2023.102196_bib26","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.esmoop.2023.102196_bib27","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102196_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.breast.2022.06.003","article-title":"Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D","volume":"65","author":"Graffeo","year":"2022","journal-title":"Breast"},{"issue":"8","key":"10.1016\/j.esmoop.2023.102196_bib29","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.esmoop.2023.102196_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.661464","article-title":"Arterial stiffness: effects of anticancer drugs used for breast cancer women","volume":"12","author":"Novo","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.esmoop.2023.102196_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.867873","article-title":"Genetics of anthracycline-associated cardiotoxicity","volume":"9","author":"Al-Otaibi","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102196_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11936-018-0609-z","article-title":"Cardiovascular concerns in BRCA1 and BRCA2 mutation carriers","volume":"20","author":"Gast","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.esmoop.2023.102196_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.maturitas.2016.06.012","article-title":"Cardiovascular risk of BRCA1\/2 mutation carriers: a review","volume":"91","author":"van Westerop","year":"2016","journal-title":"Maturitas"},{"key":"10.1016\/j.esmoop.2023.102196_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.833171","article-title":"Mutations and cardiovascular function in breast cancer survivors","volume":"9","author":"Demissei","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.esmoop.2023.102196_bib35","article-title":"Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals","volume":"10","author":"Bisceglia","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102196_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100461","article-title":"Anthracyclines in the treatment of patients with early breast cancer","volume":"7","author":"Guarneri","year":"2022","journal-title":"ESMO Open"},{"issue":"25","key":"10.1016\/j.esmoop.2023.102196_bib37","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.102196_bib38","article-title":"Cardiac toxicity from adjuvant targeting treatment for breast cancer post-surgery","volume":"12","author":"Fu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2023.102196_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103567","article-title":"The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: a position paper on behalf of the AIOM-SIAPEC\/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies","volume":"169","author":"Russo","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2023.102196_bib40","article-title":"Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2023.102196_bib41","first-page":"S725","article-title":"Cardiotoxicity in patients treated with PARP-inhibitors","volume":"32","author":"Clemente","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102196_bib42","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/gme.0b013e3182517bd0","article-title":"Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis","volume":"19","author":"Wellons","year":"2012","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102196_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2014.01.008","article-title":"BRCA1\/2 mutation carriers are potentially at higher cardiovascular risk","volume":"91","author":"Arts-de Jong","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2023.102196_bib44","doi-asserted-by":"crossref","first-page":"102650","DOI":"10.1016\/j.ctrv.2023.102650","article-title":"Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?","volume":"121","author":"Incorvaia","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2023.102196_bib45","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s10554-023-02897-9","article-title":"Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices","volume":"39","author":"Di Lisi","year":"2023","journal-title":"Int J Cardiovasc Imaging"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923014370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923014370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:30:08Z","timestamp":1761856208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923014370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2059702923014370"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102196","relation":{},"ISSN":["2059-7029"],"issn-type":[{"type":"print","value":"2059-7029"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102196"}}